New Therapies for Secondary Progressive Multiple Sclerosis

This 15-minute accredited CME publication reviews the mechanisms of action and clinical data of 2 new approved therapies for active secondary progressive multiple sclerosis (SPMS). Highlights include a discussion on SPMS pathophysiology and how newer therapies may address both the inflammatory and degenerative aspects of the disease. In addition, this activity features a short video that provides expert commentary from Mark Skeen, MD, on the current management landscape for patients with SPMS.

Format
Online Publication
Cost
Complimentary
Credit
0.25 AMA PRA Category 1 Credit™

Mark B. Skeen, MD, FACP, FAAN
Associate Professor of Neurology
Head, Division of Multiple Sclerosis and Neuroimmunology